✦ LIBER ✦

Ocrelizumab in multiple sclerosis: risks and benefits

✍ Scribed by Abhijit Chaudhuri

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ocrelizumab in multiple sclerosis: risks

✍ Ludwig Kappos; David Leppert; Jeroen Timmermann; Robert Glanzman; Stephen Hauser 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 80 KB

Mitoxantrone: benefits and risks in mult

✍ V. Martinelli; M. Radaelli; L. Straffi; M. Rodegher; G. Comi 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 119 KB

Autologous haematopoietic stem-cell tran

✍ E. Capello; L. Vuolo; F. Gualandi; M. T. Van Lint; L. Roccatagliata; L. Bonzano; 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 120 KB

Cyclophosphamide as second-line therapy

✍ Luciano Rinaldi; P. Perini; M. Calabrese; P. Gallo 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 137 KB

PND3 Risk-Benefit Analysis of Therapy in

✍ N. Qizilbash; I. Méndez; R. Sánchez-de la Rosa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Ocrelizumab in relapsing-remitting multi

✍ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 337 KB